vs
Side-by-side financial comparison of Stanley Black & Decker (SWK) and Viatris (VTRS). Click either name above to swap in a different company.
Stanley Black & Decker is the larger business by last-quarter revenue ($3.8B vs $3.7B, roughly 1.0× Viatris). On growth, Viatris posted the faster year-over-year revenue change (5.0% vs 0.1%). Viatris produced more free cash flow last quarter ($619.3M vs $155.3M). Over the past eight quarters, Viatris's revenue compounded faster (0.5% CAGR vs 0.3%).
Stanley Black & Decker, Inc., formerly known as The Stanley Works, is an American manufacturer of industrial tools and household hardware, and a provider of security products. Headquartered in the Greater Hartford city of New Britain, Connecticut, Stanley Black & Decker is the result of the merger of The Stanley Works and Black & Decker on March 12, 2010.
Viatris Inc. is an American global pharmaceutical and healthcare corporation headquartered in Canonsburg, Pennsylvania. The corporation was formed through the merger of Mylan and Upjohn, a legacy division of Pfizer, on November 16, 2020.
SWK vs VTRS — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $3.8B | $3.7B |
| Net Profit | $51.4M | — |
| Gross Margin | 31.4% | 31.1% |
| Operating Margin | — | -5.2% |
| Net Margin | 1.4% | — |
| Revenue YoY | 0.1% | 5.0% |
| Net Profit YoY | -43.6% | — |
| EPS (diluted) | $0.34 | $-0.34 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $3.7B | ||
| Q3 25 | $3.8B | $3.7B | ||
| Q2 25 | $3.9B | $3.6B | ||
| Q1 25 | $3.7B | $3.2B | ||
| Q4 24 | $3.7B | $3.5B | ||
| Q3 24 | $3.8B | $3.7B | ||
| Q2 24 | $4.0B | $3.8B | ||
| Q1 24 | $3.9B | $3.7B |
| Q4 25 | — | — | ||
| Q3 25 | $51.4M | — | ||
| Q2 25 | $101.9M | — | ||
| Q1 25 | $90.4M | — | ||
| Q4 24 | $194.9M | — | ||
| Q3 24 | $91.1M | — | ||
| Q2 24 | $-11.2M | — | ||
| Q1 24 | $19.5M | — |
| Q4 25 | — | 31.1% | ||
| Q3 25 | 31.4% | 36.6% | ||
| Q2 25 | 27.0% | 37.3% | ||
| Q1 25 | 29.9% | 35.8% | ||
| Q4 24 | 30.8% | 34.6% | ||
| Q3 24 | 29.9% | 39.0% | ||
| Q2 24 | 28.4% | 38.2% | ||
| Q1 24 | 28.6% | 41.2% |
| Q4 25 | — | -5.2% | ||
| Q3 25 | — | 4.8% | ||
| Q2 25 | — | 6.5% | ||
| Q1 25 | — | -88.9% | ||
| Q4 24 | 3.4% | -5.1% | ||
| Q3 24 | 10.6% | 6.0% | ||
| Q2 24 | 9.5% | -6.3% | ||
| Q1 24 | 8.3% | 5.6% |
| Q4 25 | — | — | ||
| Q3 25 | 1.4% | — | ||
| Q2 25 | 2.6% | — | ||
| Q1 25 | 2.4% | — | ||
| Q4 24 | 5.2% | — | ||
| Q3 24 | 2.4% | — | ||
| Q2 24 | -0.3% | — | ||
| Q1 24 | 0.5% | — |
| Q4 25 | — | $-0.34 | ||
| Q3 25 | $0.34 | $-0.11 | ||
| Q2 25 | $0.67 | $0.00 | ||
| Q1 25 | $0.60 | $-2.55 | ||
| Q4 24 | $1.29 | $-0.43 | ||
| Q3 24 | $0.60 | $0.08 | ||
| Q2 24 | $-0.07 | $-0.27 | ||
| Q1 24 | $0.13 | $0.09 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $268.3M | $1.3B |
| Total DebtLower is stronger | $5.3B | — |
| Stockholders' EquityBook value | $9.0B | $14.7B |
| Total Assets | $21.8B | $37.2B |
| Debt / EquityLower = less leverage | 0.59× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $1.3B | ||
| Q3 25 | $268.3M | $975.3M | ||
| Q2 25 | $311.8M | $566.4M | ||
| Q1 25 | $344.8M | $755.0M | ||
| Q4 24 | $290.5M | $734.8M | ||
| Q3 24 | $298.7M | $1.9B | ||
| Q2 24 | $318.5M | $917.2M | ||
| Q1 24 | $476.6M | $1.0B |
| Q4 25 | — | — | ||
| Q3 25 | $5.3B | — | ||
| Q2 25 | $5.6B | — | ||
| Q1 25 | $5.6B | — | ||
| Q4 24 | $6.1B | — | ||
| Q3 24 | $6.1B | — | ||
| Q2 24 | $6.1B | — | ||
| Q1 24 | $6.1B | — |
| Q4 25 | — | $14.7B | ||
| Q3 25 | $9.0B | $15.2B | ||
| Q2 25 | $9.1B | $15.6B | ||
| Q1 25 | $8.8B | $15.7B | ||
| Q4 24 | $8.7B | $18.6B | ||
| Q3 24 | $8.9B | $19.8B | ||
| Q2 24 | $8.7B | $19.5B | ||
| Q1 24 | $8.9B | $20.0B |
| Q4 25 | — | $37.2B | ||
| Q3 25 | $21.8B | $37.9B | ||
| Q2 25 | $22.5B | $38.4B | ||
| Q1 25 | $22.5B | $38.5B | ||
| Q4 24 | $21.8B | $41.5B | ||
| Q3 24 | $22.5B | $44.8B | ||
| Q2 24 | $22.5B | $45.3B | ||
| Q1 24 | $23.9B | $47.3B |
| Q4 25 | — | — | ||
| Q3 25 | 0.59× | — | ||
| Q2 25 | 0.62× | — | ||
| Q1 25 | 0.63× | — | ||
| Q4 24 | 0.70× | — | ||
| Q3 24 | 0.69× | — | ||
| Q2 24 | 0.70× | — | ||
| Q1 24 | 0.69× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $221.2M | $815.8M |
| Free Cash FlowOCF − Capex | $155.3M | $619.3M |
| FCF MarginFCF / Revenue | 4.1% | 16.8% |
| Capex IntensityCapex / Revenue | 1.8% | 5.3% |
| Cash ConversionOCF / Net Profit | 4.30× | — |
| TTM Free Cash FlowTrailing 4 quarters | $369.6M | $1.9B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $815.8M | ||
| Q3 25 | $221.2M | $744.9M | ||
| Q2 25 | $214.3M | $219.7M | ||
| Q1 25 | $-420.0M | $535.5M | ||
| Q4 24 | $679.1M | $482.7M | ||
| Q3 24 | $285.8M | $826.5M | ||
| Q2 24 | $573.0M | $379.1M | ||
| Q1 24 | $-431.0M | $614.6M |
| Q4 25 | — | $619.3M | ||
| Q3 25 | $155.3M | $658.1M | ||
| Q2 25 | $134.7M | $166.8M | ||
| Q1 25 | $-485.0M | $492.9M | ||
| Q4 24 | $564.6M | $342.3M | ||
| Q3 24 | $199.3M | $749.5M | ||
| Q2 24 | $485.8M | $320.3M | ||
| Q1 24 | $-496.7M | $564.8M |
| Q4 25 | — | 16.8% | ||
| Q3 25 | 4.1% | 17.6% | ||
| Q2 25 | 3.4% | 4.7% | ||
| Q1 25 | -13.0% | 15.2% | ||
| Q4 24 | 15.2% | 9.7% | ||
| Q3 24 | 5.3% | 20.1% | ||
| Q2 24 | 12.1% | 8.5% | ||
| Q1 24 | -12.8% | 15.5% |
| Q4 25 | — | 5.3% | ||
| Q3 25 | 1.8% | 2.3% | ||
| Q2 25 | 2.0% | 1.5% | ||
| Q1 25 | 1.7% | 1.3% | ||
| Q4 24 | 3.1% | 4.0% | ||
| Q3 24 | 2.3% | 2.1% | ||
| Q2 24 | 2.2% | 1.6% | ||
| Q1 24 | 1.7% | 1.4% |
| Q4 25 | — | — | ||
| Q3 25 | 4.30× | — | ||
| Q2 25 | 2.10× | — | ||
| Q1 25 | -4.65× | — | ||
| Q4 24 | 3.48× | — | ||
| Q3 24 | 3.14× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -22.10× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
SWK
| Tools And Outdoor Segment | $3.3B | 87% |
| Engineered Fastening Segment | $500.5M | 13% |
VTRS
| Brands | $1.2B | 32% |
| Generics | $1.1B | 29% |
| Lipitor | $377.3M | 10% |
| Norvasc | $175.2M | 5% |
| Other | $136.6M | 4% |
| Lyrica | $119.8M | 3% |
| Viagra | $104.2M | 3% |
| Creon | $98.9M | 3% |
| Epi Pen Auto Injectors | $79.0M | 2% |
| Yupelri | $70.6M | 2% |
| Effexor | $68.1M | 2% |
| Zoloft | $66.8M | 2% |
| Celebrex | $66.2M | 2% |
| Xalabrands | $42.0M | 1% |
| Dymista | $38.6M | 1% |
